| Recipient E-mail
Nearly a fourth of the nuclear reactors in the U.S., 24 out of 104, are in drought afflicted regions. Nearly all, 22 of these 24, rely on lakes and rivers for their water needs. The Nuclear Regulatory Commission, the U.S. government body which regulates the nuclear power industry, has set minimum allowable water levels for these water sources. Most of the water sources are approaching these minimum levels. Falling below means a government mandated plant closure. Even if the government relaxes its restrictions, the water levels are forecasted to drop below the level of the intake pipes for many of these plants. At other plants, the water is becoming too hot under the sun and from stored up heat to be used for cooling purposes. Robert Yanity, a spokesman for South Carolina Electric & Gas Co.
StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting ...
MENLO PARK, Calif., Oct. 31 /PRNewswire/ -- StemCor Systems, Inc., a medical device company developing systems for Enabling Regenerative Medicine(TM), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its MarrowMiner(TM) for the harvest of bone marrow. "Regulatory clearance of StemCor's MarrowMiner is a major accomplishment for the Company as we develop the necessary tools to extract, process and deliver bone marrow-derived adult stem and progenitor cells," said Vartan Ghazarossian, PhD, President and CEO of StemCor Systems. "The MarrowMiner is the first minimally-invasive system for the collection of bone marrow, making marrow extraction faster, safer and more comfortable. Physicians will now be able to use this system to collect marrow from healthy donors for bone marrow transplantation, as well as from patients who are to be treated with their own marrow-derived cells, for an expanding array of current and emerging regenerative medicine applications." "We believe this novel and innovative system addresses a large unmet clinical need to gain access to sufficient adult-bone marrow derived cells in a safe, convenient and reliable manner," said Paul Yock, MD, Weiland Professor of Medicine and Bioengineering and Director, Program in Biodesign, Stanford University.
Trouble Brewing? - Merck, Schering-Plough Get New York Subpoena Over ...
1/27/2008 1:43:13 AM New York Attorney General Andrew Cuomo subpoenaed Merck & Co. Inc. (MRK) and Schering-Plough Corp. (SGP) on Saturday seeking documents to probe whether the companies had concealed the study results of their controversial blockbuster drug Vyotrin.
Cuomo in a statement said, We will investigate and, when appropriate, hold accountable drug companies for engaging in irresponsible and deceptive conduct and any deceitful marketing of prescription drugs."
The issuance of this subpoena comes a day after the FDA said it would review the effectiveness of Vyotrin after Merck released the long-awaited study results of that drug.
MRK closed Friday's trade down 3.57% or $1.77 at $47.79 on a volume of 64.98 million shares. In after-hours, the stock shed another $0.19 and was at $47.60.
|
